hydroxyurea has been researched along with Acute Edematous Pancreatitis in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 9.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| "A new notice was distributed to health care providers cautioning of the increased risk of fatal and nonfatal pancreatitis for patients taking didanosine (Videx) from Bristol-Meyers Squibb." | 7.70 | Extended warning on Didanosine-related pancreatitis. ( , 1999) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 5.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| " Incidence rates of pancreatitis were calculated for each antiretroviral regimen that included zidovudine, stavudine, didanosine (+ hydroxyurea), and didanosine + stavudine (+ hydroxyurea)." | 3.71 | Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. ( Chaisson, RE; Keruly, JC; Moore, RD, 2001) |
| "A new notice was distributed to health care providers cautioning of the increased risk of fatal and nonfatal pancreatitis for patients taking didanosine (Videx) from Bristol-Meyers Squibb." | 3.70 | Extended warning on Didanosine-related pancreatitis. ( , 1999) |
| "Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy." | 2.41 | Didanosine once daily: potential for expanded use. ( Pollard, RB, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimazu, Y | 1 |
| Fujimura, K | 1 |
| Lori, F | 1 |
| Kelly, LM | 1 |
| Foli, A | 1 |
| Lisziewicz, J | 1 |
| Reisler, RB | 1 |
| Murphy, RL | 1 |
| Redfield, RR | 1 |
| Parker, RA | 1 |
| Barie, PS | 1 |
| Tahamont, MV | 1 |
| Malik, AB | 1 |
| Pollard, RB | 1 |
| Loukopoulos, D | 1 |
| Voskaridou, E | 1 |
| Kalotychou, V | 1 |
| Schina, M | 1 |
| Loutradi, A | 1 |
| Theodoropoulos, I | 1 |
| Longhurst, HJ | 1 |
| Pinching, AJ | 1 |
| Moore, RD | 1 |
| Keruly, JC | 1 |
| Chaisson, RE | 1 |
| Havlir, DV | 1 |
| Gilbert, PB | 1 |
| Bennett, K | 1 |
| Collier, AC | 1 |
| Hirsch, MS | 1 |
| Tebas, P | 1 |
| Adams, EM | 1 |
| Wheat, LJ | 1 |
| Goodwin, D | 1 |
| Schnittman, S | 1 |
| Holohan, MK | 1 |
| Richman, DD | 1 |
| Barreiro, P | 1 |
| Soriano, V | 1 |
| Valencia, E | 1 |
| Díaz, B | 1 |
| González-Lahoz, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir With or Without Saquinavir in HIV-Infected Pediatric Subjects Previously Treated With Protease Inhibitors[NCT00084058] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | Completed | |||
| A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma[NCT00000916] | Phase 2 | 399 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxyurea and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Safety of hydroxyurea in the treatment of HIV infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dose-Response Relationship, Drug; Drug Syner | 2004 |
Didanosine once daily: potential for expanded use.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Liver; | 2000 |
4 trials available for hydroxyurea and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; HIV-1; Humans; Hydroxyure | 2005 |
Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Topics: Acute Disease; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythr | 2000 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; HIV-1; Humans; Hydroxyurea; Incidence; Pancreatitis; Re | 2001 |
6 other studies available for hydroxyurea and Acute Edematous Pancreatitis
| Article | Year |
|---|---|
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report.
Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus | 2016 |
Prevention of increased pulmonary vascular permeability after pancreatitis by granulocyte depletion in sheep.
Topics: Acute Disease; Animals; Capillary Permeability; Granulocytes; Hydroxyurea; Lung; Lymphatic System; M | 1982 |
Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine.
Topics: Acute Disease; Adult; Anti-HIV Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Hydrox | 2001 |
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Topics: Adult; Amylases; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV-1; Humans; Hydroxyurea; In | 2001 |
Extended warning on Didanosine-related pancreatitis.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hum | 1999 |
ddI, d4T, Hydroxyurea: new pancreatitis warning.
Topics: Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; H | 1999 |